ESC-HFA 2024: Late-Breaking Science Video Collection

Published: 14 May 2024

  • Views:

    Views Icon 1067

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Association’s annual congress, Heart Failure 2024. 

Dive deep into novel data with in-depth and critical discussions led by Late-breaker host Dr Harriette Van Spall and her expert guests. 

For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators.

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

Thought-provoking discussions with the investigators.
4 sessions
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie Watch now
Late-Breaker Discussion: The TITRATE-HF Study Watch now
Late-Breaker Discussion: Insights from the STEP-HFpEF Watch now
Late-Breaker Discussion: Findings from PACT-HF Watch now

Part 2

Expert Interviews

Short, practical interviews with the investigators.
8 sessions
Remote Patient Monitoring for Patients With Heart Failure: TELESAT Watch now
Cordella PA Sensor System in NYHA Class III HF Patients: PROACTIVE-HF Watch now
Aspirin Avoidance after Implantation of a Fully Magnetically Levitated LVAD: ARIES HM3 Watch now
Timing of Cardio-Kidney Protection with SGLT2i Watch now
Treatment Benefit Consistency of Remote Hemodynamic Monitoring in CHF: MONITOR-HF Subgroup Analysis Watch now
Inter-Atrial Shunt Treatment to Reduce Lung Congestion in Patients with Advanced Heart Failure: RELIEVE-HF Watch now
FINE-HEART: Design & Baseline Characteristics Watch now
HFA 24: The RELIEVE-HF Trial: Differential Effects of V-Wave Device Watch now

About the episode

HFA 24 - We are joined onsite by Dr Michael Zile (Medical University of South Carolina, US) to discuss the outcomes of the RELIEVE-HF trial.

RELIEVE-HF is designed to evaluate the safety and effectiveness of the V-Wave interatrial shunt system in patients with heart failure. 605 participants with New York Heart Association (NYHA) functional class II, class III or class IV heart failure, who had been treated with guideline-directed drug and device therapies were enrolled in the trial, and randomized 1:1 to recieve either the interatrial shunt, or were part of the control arm. In this interview, Dr Zile outlines the differencial effects of inter-atrial shunt treatment on cardiac structure and function in patients with reduced vs preserved ejection fraction.

Findings showed that in HFrEF, interatrial shunt treatment was tolerated without increased right ventricular preload or afterload. In HFpEF, left and right heart were non-compliant at baseline, and remained non-compliant after interatrial shunt treatment. These findings suggest a mechanistic basis for the differences in clinical outcomes seen between both arms.

Interview Questions:

  1. What is the reasoning behind this study?
  2. Could you tell us more about the V-Wave shunt system?
  3. What was the patient population and study design?
  4. What are the key findings in regard to treament effects in patients with HFpEF and HFrEF?
  5. What are your take-home messages?
  6. Where are the knowledge gaps, and what further study is needed?

Recorded onsite at HFA 2024, Lisbon.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance
Video Specialists: Tom Green, Oliver Miles
Interviewer: Jonathan McKenna

Faculty Biographies

Michael R Zile

Michael R Zile

Charles Ezra Daniel Professor of Medicine

Dr. Zile is currently the Charles Ezra Daniel Professor of Medicine and Distinguished University Professor at the Medical University of South Carolina. He is a member of the Cardiology Division at the Ralph H. Johnson Department of Veteran's Affairs Health Care System in Charleston. He is also the Director of the SmartState SC Center of Economic Excellence: Molecular Proteomics in Cardiovascular Disease, Prevention and Treatment. He is an Adjunct Professor of Bioengineering at Clemson University. He is the 2019 William S. Middleton Awardee for Outstanding Achievement in Biomedical Research and the 2020 South Carolina Governor’s Awardee for Excellence in Scientific Research. Dr. Zile's research career has focused on basic, translational and clinical research examining the mechanisms underlying the development and progression of heart failure; and determining how these mechanisms can be used to develop effective diagnostic, prognostic and treatment methods for…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.